Studio sul Diabete di Tipo 2 INtrattabile (CAPTAIN-T2D) (CAPTAIN-T2D)
Clofutriben e Placebo Studio di Fase 2 contro il Diabete di Tipo 2 Intrattabile (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Chandler, Arizona, Stati Uniti, 85225
- Reclutamento
- Arizona Clinical Trials - Pecos
-
Contatto:
- Kamila Manager
- Numero di telefono: 480-470-4000
- Email: kojeda@azclinicaltrials.com
-
Tucson, Arizona, Stati Uniti, 85711
- Reclutamento
- Arizona Clinical Trials - Broadway
-
Contatto:
- Leanne Manager
- Numero di telefono: 480-470-4000
- Email: lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley, California, Stati Uniti, 92708
- Reclutamento
- Ark Clinical Research - Fountain Valley
-
Contatto:
- Lizeth Manager
- Numero di telefono: 323-588-1990
- Email: lsuncin@velocityclinical.com
-
Huntington Park, California, Stati Uniti, 90255
- Reclutamento
- Velocity Clinical Research, Huntington Park
-
Contatto:
- Tim Manager
- Numero di telefono: 5135799911
- Email: tpeterson@velocityclinical.com
-
La Mesa, California, Stati Uniti, 91942
- Reclutamento
- Velocity Clinical Research - Gardena
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Long Beach, California, Stati Uniti, 90815
- Reclutamento
- Ark Clinical Research - Long Beach
-
Contatto:
- Mike Manager
- Numero di telefono: 562-997-1000
- Email: mdelgado@arkclinicalresearch.com
-
Los Angeles, California, Stati Uniti, 90057
- Reclutamento
- Velocity Clinical Research, Los Angeles
-
Contatto:
- Tim Manager
- Numero di telefono: 5135799911
- Email: tpeterson@velocityclinical.com
-
Los Angeles, California, Stati Uniti, 90015
- Reclutamento
- Los Angeles Institute for Metabolic Research
-
Contatto:
- Lourdes Manager
- Numero di telefono: (213) 373-8380
- Email: lgaribay@metabolic.la
-
Northridge, California, Stati Uniti, 98433
- Reclutamento
- Amicis Research Center- Nordhoff
-
Contatto:
- Veronica Clinical Research Manager
- Numero di telefono: (818) 929-7774
- Email: veronica.macias@amicisresearch.com
-
San Diego, California, Stati Uniti, 92120
- Reclutamento
- Alliance Clinical San Diego
-
Contatto:
- Sandra Manager
- Numero di telefono: (858) 299-0009
- Email: SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater, Florida, Stati Uniti, 32132
- Reclutamento
- Velocity Clinical Research, New Smyrna Beach
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Fort Lauderdale, Florida, Stati Uniti, 33312
- Reclutamento
- The Center for Diabetes and Endocrine Care
-
Contatto:
- Marie Study Coordinator
- Numero di telefono: ext 236 954-963-7191
- Email: mmartin@diabetes-endocare.com
-
Miami, Florida, Stati Uniti, 33173
- Reclutamento
- Admed Research LLC
-
Contatto:
- Indiana Manager
- Numero di telefono: 786-687-2882
- Email: igonzalez@admedresearch.com
-
New Port Richey, Florida, Stati Uniti, 34652
- Reclutamento
- Suncoast Clinical Research, Inc
-
Contatto:
- Cathy Manager
- Numero di telefono: 727-849-4131
- Email: cbarnes@suncoastclinicalresearch.com
-
Port Charlotte, Florida, Stati Uniti, 33952
- Reclutamento
- Innovative Research Institute
-
Contatto:
- Lauren Manager
- Numero di telefono: (+1) 2832276233
- Email: l.ellis@medpace.com
-
Port Orange, Florida, Stati Uniti, 32127
- Reclutamento
- Progressive Medical Research
-
Contatto:
- Nora Clinical Research Manager
- Numero di telefono: 3457 386-304-7070
- Email: norab@progressivemedicalresearch.com
-
Winter Park, Florida, Stati Uniti, 32789
- Reclutamento
- Conquest Research
-
Contatto:
- Malisa Manager
- Numero di telefono: 407-916-0060
- Email: malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30303
- Reclutamento
- Emory University School of Medicine
-
Contatto:
- Rohit Manager
- Numero di telefono: 404-778-1695
- Email: rohit.parab@emory.edu
-
Columbus, Georgia, Stati Uniti, 31904
- Reclutamento
- IACT Health-Brookstone Centre Pkwy
-
Contatto:
- kristina Manager
- Numero di telefono: 706.321.0495
- Email: kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise, Idaho, Stati Uniti, 83709
- Reclutamento
- Paradigm Clinical Research - Boise, ID
-
Contatto:
- Janaie Manager
- Numero di telefono: 208-801-7440
- Email: jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60607
- Reclutamento
- Chicago Clinical Research Institute
-
Contatto:
- Manognya Clinical Research Manager
- Numero di telefono: 303 3127913241
- Email: manognya@ccrii.us
-
-
Iowa
-
West Des Moines, Iowa, Stati Uniti, 50226
- Reclutamento
- Iowa Diabetes and Endocrinology Research Center
-
Contatto:
- Crystal Manager
- Numero di telefono: 515-207-7486
- Email: choffman@iderc.com
-
-
Kansas
-
Wichita, Kansas, Stati Uniti, 67226
- Reclutamento
- Alliance for Multispecialty Research - Wichita East
-
Contatto:
- Terry Manager
- Numero di telefono: 316-689-6635
- Email: terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood, Kentucky, Stati Uniti, 41017
- Reclutamento
- St. Elizabeth Healthcare
-
Contatto:
- Amber Manager
- Numero di telefono: 859-655-1567
- Email: amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette, Louisiana, Stati Uniti, 70508
- Reclutamento
- Velocity Clinical Research, Lafayette
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- NOLA Care Clinical Research
-
Contatto:
- Rosina Manager
- Numero di telefono: 504-427-6324
- Email: rosinaducote@gmail.com
-
New Orleans, Louisiana, Stati Uniti, 70112
- Reclutamento
- Tulane University School of Medicine
-
Contatto:
- Neha Manager
- Numero di telefono: 5049889803
- Email: nupadhyay@tulane.edu
-
-
Maryland
-
Rockville, Maryland, Stati Uniti, 20854
- Reclutamento
- Velocity Clinical Research, Rockville
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield, Massachusetts, Stati Uniti, 011030
- Reclutamento
- Elixia SISU BHR - Springfield
-
Contatto:
- Darlene Manager
- Numero di telefono: 5617970336
- Email: darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy, Michigan, Stati Uniti, 48085
- Reclutamento
- Oakland Medical Research Center
-
Contatto:
- Juliejo (Julie) Clinical Research Manager
- Numero di telefono: 248-687-7412
- Email: juliejolafave@msn.com
-
-
Nebraska
-
Lincoln, Nebraska, Stati Uniti, 68510
- Reclutamento
- Velocity Clinical Research, Lincoln
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Omaha, Nebraska, Stati Uniti, 68134
- Reclutamento
- Velocity Clinical Research, Omaha
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89148
- Reclutamento
- Palm Research Center, Inc.
-
Contatto:
- Raffaela Manager
- Numero di telefono: 702-736-5161
- Email: raffaela@palmresearchcenter.com
-
Las Vegas, Nevada, Stati Uniti, 89108
- Reclutamento
- Alliance Clinical - Las Vegas
-
Contatto:
- Stephanie Manager
- Numero di telefono: (702) 680-1500
- Email: sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany, New York, Stati Uniti, 12203
- Reclutamento
- Albany Medical College
-
Contatto:
- Mohammed Manager
- Numero di telefono: 518-264-4462
- Email: ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Reclutamento
- University of North Carolina at Chapel Hill
-
Contatto:
- Jessica Manager
- Numero di telefono: 984-974-3004
- Email: jessica_caffey@med.unc.edu
-
Greenville, North Carolina, Stati Uniti, 27834
- Reclutamento
- Physicians East
-
Contatto:
- Kristen Manager
- Numero di telefono: 252-413-6392
- Email: ktaylor@physicianseast.com
-
Morehead City, North Carolina, Stati Uniti, 28557
- Reclutamento
- Lucas Research Inc
-
Contatto:
- Christina Manager
- Numero di telefono: 252-222-5700
- Email: christina.tornes@centricityresearch.com
-
Wilmington, North Carolina, Stati Uniti, 28401
- Reclutamento
- PMG Research of Wilmington, LLC
-
Contatto:
- Kevin Manager
- Numero di telefono: 910.815.6108
- Email: cannon1099@me.com
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Cincinnati, Ohio, Stati Uniti, 45242
- Reclutamento
- Velocity Clinical Research - Cincinnati, Blue Ash
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Columbus, Ohio, Stati Uniti, 43201
- Reclutamento
- Endocrinology Associates, Inc
-
Contatto:
- Edward Clinical Research Manager
- Numero di telefono: 614-453-9999
- Email: ek@endocrinology-associates.com
-
Columbus, Ohio, Stati Uniti, 43215
- Reclutamento
- Remington Davis, Inc
-
Contatto:
- Tsunami Clinical Research Manager
- Numero di telefono: 614-487-2560
- Email: Tbrisco@remdavis.com
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97404
- Reclutamento
- Willamette Valley Clinical Studies
-
Contatto:
- Patricia Manager
- Numero di telefono: 541-461-0132
- Email: drpatb@aol.com
-
-
Pennsylvania
-
West Chester, Pennsylvania, Stati Uniti, 19380
- Reclutamento
- Suburban Research Associates
-
Contatto:
- Tom Manager
- Numero di telefono: 610-891-9024
- Email: tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson, South Carolina, Stati Uniti, 29621
- Reclutamento
- Velocity Clinical Research, Anderson
-
Contatto:
- Tim Manager
- Numero di telefono: (864) 965-0190
- Email: tpeterson@velocityclinical.com
-
Mt. Pleasant, South Carolina, Stati Uniti, 29464
- Reclutamento
- Accellacare Charleston
-
Contatto:
- Dhruva Manager
- Numero di telefono: (843) 849-1880
- Email: dhruva.patel@accellacare.com
-
-
Texas
-
Austin, Texas, Stati Uniti, 78759
- Reclutamento
- Velocity Clinical Research, Austin
-
Contatto:
- Tim Manager
- Numero di telefono: 513-673-4057
- Email: tpeterson@velocityclinical.com
-
Dallas, Texas, Stati Uniti, 75230
- Reclutamento
- Velocity Clinical Research - Dallas
-
Contatto:
- Tim Manager
- Numero di telefono: (972) 566-8631
- Email: tpeterson@velocityclinical.com
-
Houston, Texas, Stati Uniti, 77040
- Reclutamento
- Juno Research, LLC
-
Contatto:
- Lian manager
- Numero di telefono: 713-779-5494
- Email: lian_ramos@junoresearch.us
-
Lampasas, Texas, Stati Uniti, 76550
- Reclutamento
- Radiance Clinical Research
-
Contatto:
- Lauren Clinical Research Manager
- Numero di telefono: 512-556-4130
- Email: lgarner@radianceclinical.com
-
Lewisville, Texas, Stati Uniti, 75057
- Reclutamento
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
Contatto:
- Jessica Manager
- Numero di telefono: (469) 361-8007
- Email: jpowell@allianceclinicalnetwork.com
-
Mission, Texas, Stati Uniti, 78572
- Reclutamento
- Texas Valley Clinical Research - Mission, TX
-
Contatto:
- Omar Manager
- Numero di telefono: 9568887400
- Email: gonzalez.md@tvcrmission.com
-
Round Rock, Texas, Stati Uniti, 78681
- Reclutamento
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
Contatto:
- Olivia Clinical Research Manager
- Numero di telefono: 512-334-3505
- Email: knutty@tderesearch.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Diabetes & Glandular Disease Clinic, P.A.
-
Contatto:
- Myriam Manager
- Numero di telefono: 1532 210-614-8612
- Email: myriam.turner@dgdclinic.com
-
San Antonio, Texas, Stati Uniti, 78251
- Reclutamento
- Texas Valley Clinical Research - San Antonio TX
-
Contatto:
- Diana Manager
- Numero di telefono: 2105431990
- Email: diana@tvcrtrials.com
-
Seabrook, Texas, Stati Uniti, 77586
- Reclutamento
- Elevate Clinical Research
-
Contatto:
- Olga Clinical Research Manager
- Numero di telefono: 832-271-1598
- Email: olga.konshina@elevateclinical.com
-
Weslaco, Texas, Stati Uniti, 78596
- Reclutamento
- Texas Valley Clinical Research, LLC
-
Contatto:
- Czarina Manager
- Numero di telefono: 956-431-8090
- Email: czarina@tvcrtrials.com
-
-
Utah
-
West Jordan, Utah, Stati Uniti, 84088
- Reclutamento
- Velocity Clinical Research, Salt Lake City
-
Contatto:
- Tim Clinical Research Manager
- Numero di telefono: 5135799911
- Email: tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk, Virginia, Stati Uniti, 23435
- Reclutamento
- Velocity Clinical Research, Suffolk
-
Contatto:
- Tim Manager
- Numero di telefono: (757) 996-4200
- Email: tpeterson@velocityclinical.com
-
Vienna, Virginia, Stati Uniti, 22182
- Reclutamento
- Conquest Research
-
Contatto:
- Henry Manager
- Numero di telefono: 703-372-3268
- Email: Henry.Tran@conquestresearch.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
Altri nomi:
|
|
Sperimentale: Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
Altri nomi:
|
|
Sperimentale: Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
Altri nomi:
|
|
Sperimentale: Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
Altri nomi:
|
|
Comparatore placebo: placebo
placebo control oral tablet daily |
Placebo |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Lasso di tempo: 8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Lasso di tempo: 24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Lasso di tempo: 24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
Lasso di tempo: From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Neoplasie
- Malattie metaboliche
- Disturbi del metabolismo del glucosio
- Diabete mellito
- Sindromi paraneoplastiche
- Malattie della ghiandola surrenale
- Iperfunzione surrenalica
- Sindromi endocrine paraneoplastiche
- Malattie nutrizionali e metaboliche
- Diabete mellito, tipo 2
- Sindrome di Cushing
- Sindrome da ACTH, ectopica
- ASP3662
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SPI-62-CL-2006
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .